Following the watershed approval of Iovances’ Lifileucel, all eyes are now on TIL therapies as the up-and-coming major therapeutic avenue for solid tumor treatment.

The 6th Annual TIL Therapies Summit returns to Boston as the only meeting putting the entire spotlight on TIL drug development, giving you an unmissable opportunity to capitalize on the wave of excitement into this field, as the blockbuster potential of harnessing TILs is now realized with the regulatory seal of approval.  

Join 30+ key industry speakers including Iovance Biotherapeutics, Obsidian Therapeutics, KSQ Therapeutics and the MD Anderson Cancer Center, as they unveil the latest to share clinical updates, next-generation candidates, manufacturing innovations, and assay characterizations to turbocharge development of the next wave of TIL therapies.

With a brand-new 2 tracked agenda, tailor your learning experience across pre-clinical and translation versus clinical strategy and manufacturing to leverage your entire team’s expertise among laser focused stakeholders. This year will be the biggest edition yet, as the niche community rapidly expands to seize novel opportunities.